YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Arcus Biosciences recently announced it would host an in-person investor event on October 20, 2026, in New York City to present new ARC-20 platform data on its investigational HIF-2a inhibitor casdatifan across first-, second-, and late-li…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an inv…
HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revisi…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The fair value estimate for Arcus Biosciences has shifted from US$3…
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS) breached their fiduciary duties to shareholders…
Summit Therapeutics SMMT reported a second-quarter 2026 loss per share of 28 cents, wider than the Zacks Consensus Estimate of a loss of 26 cents per share. In the year-ago period, the company had incurred a loss of 76 cents per share. The…
This article first appeared on GuruFocus. Release Date: July 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Summit Therapeutics Inc (NASDAQ:SMMT) reported a str…
Summit Therapeutics SMMT announced updated overall survival ("OS") data from the phase III HARMONi study evaluating its investigational antibody ivonescimab in certain patients with non-small cell lung cancer ("NSCLC"). The company reporte…
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy Enrollment is expected to begin in…
Data Expected to Be Generated by Mid-2027 HAYWARD, Calif. & MIAMI, July 22, 2026--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and…
Data Expected to Be Generated by Mid-2027 HAYWARD, Calif. & MIAMI, July 22, 2026--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and…
Juan C. Jaen, the president of Arcus Biosciences, Inc. (NYSE:RCUS), reported a sale of 68,569 shares on July 9, 2026 and July 10, 2026, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value $2.0 million Shar…
Bristol-Myers Squibb Company (NYSE:BMY) is one of billionaire Cliff Asness' top 10 healthcare stock picks. On June 3, Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE:B…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (NYSE:BMY) is rolling out an AI driven overhaul of its procurement operations,…
Arcus Biosciences RCUS announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMY to evaluate casdatifan in combination with PD L1/VEGF A bispecific immunomodulator. This collaboration is aimed at developin…
(RTTNews) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Wednesday a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY). Under the agreement, Arcus will supply casdatifan, the company's…
This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need HAYWARD, Calif., June 03, 2026--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: R…
HAYWARD, Calif., May 26, 2026--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflamm…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eisai’s updated analyst model now points to a fair value price target of ¥5,076.92, compared with the prior ¥5,009.23, givin…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Arcus Biosciences (NYSE:RCUS) ended its Phase 3 STAR-121 lung cance…
Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30.…
The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in asses…
Arcus Biosciences and Gilead Sciences recently discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies for domvanalimab and zimberelimab in metastatic non-small cell lung cancer after a pre-planned futility analysis, while reportin…
In April 2026, Arcus Biosciences said Gilead Sciences chose not to make a continuation payment, ending option rights to several early-stage Arcus programs while keeping time-limited options on select assets like AB801, AB598, AB102 and a T…
Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.8% higher at $24.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.2%…
Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2% Y…
Arcus Biosciences logo Key Points Updated ARC-20 single-agent data show casdatifan (100 mg QD) with a confirmed ORR rising to 45% and median PFS of 15.1 months, which Arcus says compares favorably to belzutifan in late-line ccRCC. Phase II…
TG Therapeutics TGTX reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents per share in the year-ago quart…
Intellia Therapeutics NTLA reported a fourth-quarter 2025 loss of 83 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of 99 cents. In the year-ago qu…
Alkermes plc ALKS reported adjusted earnings from continuing operations of 46 cents per share for the fourth quarter of 2025, which beat the Zacks Consensus Estimate of 43 cents. The company registered earnings of $1.04 per share in the ye…
Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc. (NYSE:RCUS) was downgraded to Equal Weight from Overweight at Wells Fargo, with the firm b…
Gilead Sciences, Inc. GILD reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.86, which beat the Zacks Consensus Estimate of $1.83. The bottom line was down from $1.90 reported a year ago. The year-over-year decrease was…
An updated edition of the December 17, 2025, article. The global oncology market is entering a phase of accelerated transformation, driven by rising cancer incidence, demographic shifts and rapid scientific progress. The American Cancer So…
Company Logo The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in en…
Key Points 82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, leaving the insider with 367,…